FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366716825> ?p ?o ?g. }

• W4366716825 endingPage "235" @default.
• W4366716825 startingPage "235" @default.
• W4366716825 abstract "Abstract Introduction Most ADHD treatments are thought to be effective due to augmentation of dopamine (DA) and norepinephrine (NE). Our prior preclinical studies found that the ADHD treatment, viloxazine, may augment serotonin (5-HT) in addition to NE and DA; however, it was unclear if these effects occurred at clinically relevant concentrations. To further understand these potential 5-HT effects, we conducted a series of experiments with two objectives: 1) Can we confirm and better elucidate the previously observed serotonergic effects of viloxazine and determine if they occur at clinically relevant concentrations? 2) Are these effects observed in species with close physiology to humans? Methods Objective 1: The affinity of viloxazine for human isoforms of 5-HT 2A , 5-HT 2B , 5-HT 2C , and 5-HT 7 receptors was assessed via cell-based binding assays. Viloxazine agonism of 5-HT 2C and antagonism at 5-HT 7 was elucidated with IP 1 , Ca 2+ , β-arrestin, internalization, and cAMP assays in cells expressing human receptor isoforms. A microdialysis study was conducted in rats to determine the relationship between viloxazine concentrations in the interstitial fluid (ISF) and changes in NE, DA, 5-HT, and their metabolite concentrations in the prefrontal cortex (PFC). Objective 2: A PET imaging study using a 5-HT 2A/2C radioligand agonist, [ 11 C]CIMBI-36, is being conducted in non-human primates (NHPs) to evaluate if viloxazine binds these receptors and/or increases 5-HT release. Animal research was approved by animal care and use committees. Animals were cared for according to international standards. Results Objective 1: Cell-based assays to measure viloxazine affinity for NET, 5-HT 2B , 5-HT 2C , and 5-HT 7 found K i values of 0.14, 0.65, 0.84, 1.90 μM respectively. These values were lower than therapeutically relevant rat ISF concentrations (3.5 ± 1.6 μM) approximating pediatric ADHD patients unbound plasma concentrations (2.1-3.3 μM), indicating receptor recruitment. Binding affinity and functional activity assays found viloxazine had negligible activity for 5-HT 2A and SERT at therapeutic concentrations. Viloxazine 5-HT 2C agonism activated G q -protein signaling (EC 50 =1.6 μM, Ca 2+ assay), but not β-arrestin or internalization pathways (EC 50 values >150 μM). Viloxazine 5-HT 7 antagonism decreased G s -protein signaling (IC 50 =6.7 μM). The microdialysis study found that at therapeutically relevant ISF concentrations, 5-HT levels were significantly increased over baseline; no changes were seen in the 5-HIAA metabolite, indicating 5-HT increase is not due to 5-HT reuptake inhibition. Objective 2: PET imaging studies are ongoing. Conclusions To date, our experiments to further elucidate the potential 5-HT effects of viloxazine have shown that the previously observed effects of viloxazine on 5-HT receptors and its augmentation of 5-HT in rat PFC occur at clinically relevant concentrations. Further exploration is needed to ascertain if these effects occur in NHPs and are relevant to ADHD. Funding Supernus Pharmaceuticals, Inc." @default.
• W4366716825 created "2023-04-24" @default.
• W4366716825 creator A5057463661 @default.
• W4366716825 creator A5060291858 @default.
• W4366716825 creator A5060557523 @default.
• W4366716825 creator A5065690217 @default.
• W4366716825 creator A5068715811 @default.
• W4366716825 date "2023-04-01" @default.
• W4366716825 modified "2023-10-17" @default.
• W4366716825 title "Characterization of Viloxazine Effects on Cortical Serotonin Neurotransmission at Doses Relevant for ADHD Treatment" @default.
• W4366716825 doi "https://doi.org/10.1017/s1092852923001633" @default.
• W4366716825 hasPublicationYear "2023" @default.
• W4366716825 type Work @default.
• W4366716825 citedByCount "0" @default.
• W4366716825 crossrefType "journal-article" @default.
• W4366716825 hasAuthorship W4366716825A5057463661 @default.
• W4366716825 hasAuthorship W4366716825A5060291858 @default.
• W4366716825 hasAuthorship W4366716825A5060557523 @default.
• W4366716825 hasAuthorship W4366716825A5065690217 @default.
• W4366716825 hasAuthorship W4366716825A5068715811 @default.
• W4366716825 hasBestOaLocation W43667168251 @default.
• W4366716825 hasConcept C126322002 @default.
• W4366716825 hasConcept C170493617 @default.
• W4366716825 hasConcept C185592680 @default.
• W4366716825 hasConcept C25876315 @default.
• W4366716825 hasConcept C2775864247 @default.
• W4366716825 hasConcept C2778938600 @default.
• W4366716825 hasConcept C37000724 @default.
• W4366716825 hasConcept C50156730 @default.
• W4366716825 hasConcept C513476851 @default.
• W4366716825 hasConcept C53910766 @default.
• W4366716825 hasConcept C67847695 @default.
• W4366716825 hasConcept C71924100 @default.
• W4366716825 hasConcept C98274493 @default.
• W4366716825 hasConceptScore W4366716825C126322002 @default.
• W4366716825 hasConceptScore W4366716825C170493617 @default.
• W4366716825 hasConceptScore W4366716825C185592680 @default.
• W4366716825 hasConceptScore W4366716825C25876315 @default.
• W4366716825 hasConceptScore W4366716825C2775864247 @default.
• W4366716825 hasConceptScore W4366716825C2778938600 @default.
• W4366716825 hasConceptScore W4366716825C37000724 @default.
• W4366716825 hasConceptScore W4366716825C50156730 @default.
• W4366716825 hasConceptScore W4366716825C513476851 @default.
• W4366716825 hasConceptScore W4366716825C53910766 @default.
• W4366716825 hasConceptScore W4366716825C67847695 @default.
• W4366716825 hasConceptScore W4366716825C71924100 @default.
• W4366716825 hasConceptScore W4366716825C98274493 @default.
• W4366716825 hasIssue "2" @default.
• W4366716825 hasLocation W43667168251 @default.
• W4366716825 hasOpenAccess W4366716825 @default.
• W4366716825 hasPrimaryLocation W43667168251 @default.
• W4366716825 hasRelatedWork W1828383458 @default.
• W4366716825 hasRelatedWork W1969014857 @default.
• W4366716825 hasRelatedWork W1973141868 @default.
• W4366716825 hasRelatedWork W1991861361 @default.
• W4366716825 hasRelatedWork W1996696582 @default.
• W4366716825 hasRelatedWork W2004200103 @default.
• W4366716825 hasRelatedWork W2033376227 @default.
• W4366716825 hasRelatedWork W2079172254 @default.
• W4366716825 hasRelatedWork W2141273446 @default.
• W4366716825 hasRelatedWork W4206347286 @default.
• W4366716825 hasVolume "28" @default.
• W4366716825 isParatext "false" @default.
• W4366716825 isRetracted "false" @default.
• W4366716825 workType "article" @default.